<ol>
<li>Date of occurrence of the event: Nov 26, 2019</li>
<li>Company name: OBI Pharma, Inc.</li>
<li>Relationship to the Company (please enter &#8220;head office&#8221; or &#8220;subsidiaries&#8221;): Head office</li>
<li>Reciprocal shareholding ratios: Not applicable</li>
<li>Name of mass media: Commercial Times pg. B4, Liberty Times pg. C2, Economy Daily News pg. A13</li>
<li>Content reported:<br />
“OBI…. The focus for the next 2-3 years will be on 4 main topics, Phase III global clinical studies of OBI-822, OBI-888, OBI-999, and OBI-3424. The remaining projects will be handed over to China subsidiary for further development. China subsidiary will be self-financing and working towards initial public offering in China, Hong Kong, or oversea markets in 5 years…. China subsidiary will periodically transact cash capital increase for a total of 10-30 billion NTD. If cash capital increase reaches to 30 billion, OBI Pharma will reduce shareholding ratio to about 49%.”<br />
“OBI… will authorize 5 products to 100% shareholding China subsidiary, expected authorization value will be around 10-30 billion NTD as subsidiary’s cash capital increase to bring in Chinese investors for local clinical studies. OBI Pharma’s shareholding ratio of subsidiary will be decreasing over time. The subsidiary’s goal is to launch in oversea market, China, Hong Kong, or Singapore in 5 years.”<br />
“OBI will authorize China subsidiary for negotiation of international authorization, indicating market distribution has already started in China.”</li>
<li>Cause of occurrence: Clarification on News articles</li>
<li>Countermeasures: The news articles regarding the future development strategies, projects and development values, and expected fundraising location, cash amount, and launching of subsidiary “OBI Pharma Biomedicine Tech (Shanghai)” have not yet been confirmed. Company will release related updates when resolutions are being made. Please refer to MOPS for latest updates.</li>
<li>Any other matters that need to be specified: New drug development is a long process associated with high costs. It is not a guaranteed success, which may increase the risk of investment. Investors shall make prudent judgments and investments.</li>
</ol>


Leadership Team

Board of Directors

Who We Are

Pipeline

Technology

Publication Library

What We Do

Careers

People and Culture

News

Announcements

Events

What’s New

Company Profile

Corporate Governance

Stakeholder

Monthly Revenue

Annual Report

Financial Report

Stock Quote

IR Presentation

Investors

Sustainability

Contact

News & Events

People & Culture

Announcement on Change of General Manager

Explanation on news article by Economy Daily News

Clarification on news articles

Date of occurrence of the event: Nov 26, 2019 Company name: OBI Pharma, Inc. Relationship to the Company (please enter &#8220;head office&#8221; or &#8220;subsidiaries&#8221;): Head office Reciprocal shareholding ratios: Not applicable Name of mass media: Commercial Times pg. B4, Liberty Times pg. C2, Economy Daily News pg. A13 Content reported: “OBI…. The focus for the [&hellip;]

Clarification on news articles - OBI Pharma 台灣浩鼎

Default Confirmation

If you need to contact us, please fill out the following form.

By submitting this form, you agree to our <a href="/privacy-policy" target="_blank">Privacy Policy</a>.

Enter consent agreement text here.  The Consent Field will store this agreement text with the form entry in order to track what the user has consented to.

Admin Notification

New submission from {form_title}

Contact Us - EN

Compliance